Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Abstract

Letter to Blood| April 13, 2023 Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma Clinical Trials & Observations Juan Pablo Alderuccio, Juan Pablo Alderuccio 1Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL https://orcid.org/0000-0002-2690-3377 Search for other works by this author on: This Site PubMed Google Scholar Isildinha M. Reis, Isildinha M. Reis 2Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL3Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, Miami, FL Search for other works by this author on: This Site PubMed Google Scholar Jean L. Koff, Jean L. Koff 4Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA https://orcid.org/0000-0003-4414-0489 Search for other works by this author on: This Site PubMed Google Scholar Melissa C. Larson, Melissa C. Larson 5Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN Search for other works by this author on: This Site PubMed Google Scholar Dai Chihara, Dai Chihara 6Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX https://orcid.org/0000-0002-1153-2294 Search for other works by this author on: This Site PubMed Google Scholar Wei Zhao, Wei Zhao 3Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, Miami, FL Search for other works by this author on: This Site PubMed Google Scholar Sara Haddadi, Sara Haddadi 1Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL Search for other works by this author on: This Site PubMed Google Scholar Thomas M. Habermann, Thomas M. Habermann 7Division of Hematology, Mayo Clinic, Rochester, MN Search for other works by this author on: This Site PubMed Google Scholar Peter Martin, Peter Martin 8Division of Hematology/Oncology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, NY Search for other works by this author on: This Site PubMed Google Scholar Jennifer R. Chapman, Jennifer R. Chapman 9Department of Pathology and Laboratory Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL Search for other works by this author on: This Site PubMed Google Scholar Christopher Strouse, Christopher Strouse 10Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA Search for other works by this author on: This Site PubMed Google Scholar Brad S. Kahl, Brad S. Kahl 11Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO https://orcid.org/0000-0003-0459-6609 Search for other works by this author on: This Site PubMed Google Scholar Jonathon B. Cohen, Jonathon B. Cohen 4Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA https://orcid.org/0000-0002-2723-6481 Search for other works by this author on: This Site PubMed Google Scholar Jonathan W. Friedberg, Jonathan W. Friedberg 12Division of Hematology/Oncology, University of Rochester, Rochester, NY Search for other works by this author on: This Site PubMed Google Scholar James R. Cerhan, James R. Cerhan 5Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN https://orcid.org/0000-0002-7482-178X Search for other works by this author on: This Site PubMed Google Scholar Christopher R. Flowers, Christopher R. Flowers 6Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX Search for other works by this author on: This Site PubMed Google Scholar Izidore S. Lossos Izidore S. Lossos 1Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL https://orcid.org/0000-0002-9346-9013 Search for other works by this author on: This Site PubMed Google Scholar Blood (2023) 141 (15): 1888–1893. https://doi.org/10.1182/blood.2022019294 Article history Submitted: December 2, 2022 Accepted: January 25, 2023 First Edition: February 3, 2023 Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Request Permissions Cite Icon Cite Search Site Citation Juan Pablo Alderuccio, Isildinha M. Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R. Chapman, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Izidore S. Lossos; Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. Blood 2023; 141 (15): 1888–1893. doi: https://doi.org/10.1182/blood.2022019294 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBlood Search Subjects: Clinical Trials and Observations, Lymphoid Neoplasia TO THE EDITOR: Bone marrow (BM) involvement impacts stage and prognosis in lymphoma, remaining an important factor in risk-stratification scores.1,2 Positron emission tomography (PET)/computed tomography (CT) has demonstrated high sensitivity to detect focal skeletal lesions compatible with BM involvement in patients with Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL), obviating confirmatory biopsies in most patients.3-5 PET/CT is commonly integrated in the staging workup and assessment of treatment response across different lymphomas, though the ability of fluorodeoxyglucose (FDG) avidity to detect marginal zone lymphoma (MZL) remains questionable.6-8 Furthermore, whether PET/CT accurately predicts BM involvement in MZL is largely unknown. The Lugano classification supports BM evaluation by PET/CT in HL and DLBCL but acknowledges limited data in other histologies.7 MZL comprises 3 subtypes, each with unique biology, clinical features, and incidence of BM involvement.9... References 1.Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood. 2017;130(12):1409-1417.Google ScholarCrossrefSearch ADS PubMed 2.International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.CrossrefSearch ADS 3.Pakos EE, Fotopoulos AD, Ioannidis JPA. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46(6):958-963.Google Scholar 4.El-Galaly TC, d’Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30(36):4508-4514.Google ScholarCrossrefSearch ADS 5.Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013;54(8):1244-1250.Google ScholarCrossrefSearch ADS 6.National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. B-cell lymphomas, Version 5.2022. Accessed 1 October 2022. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.7.Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.Google ScholarCrossrefSearch ADS 8.Ceriani L MM, Meignan M. Present role and future perspective of PET-CT in marginal zone lymphoma. Ann Lymphoma. 2020;4(13):13.Google Scholar 9.Alderuccio JP, Kahl BS. Current treatments in marginal zone lymphoma. Oncology (Williston Park). 2022;36(4):206-215.Google ScholarPubMed 10.Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th rev ed.. IARC Press; 2017.11.Alderuccio JP, Lossos IS. Prognostic factors and risk of transformation in marginal zone lymphoma. Ann Lymphoma. 2020;4:6.Google ScholarCrossrefSearch ADS 12.Inamdar KV, Medeiros LJ, Jorgensen JL, Amin HM, Schlette EJ. Bone marrow involvement by marginal zone B-cell lymphomas of different types. Am J Clin Pathol. 2008;129(5):714-722.Google ScholarCrossrefSearch ADS PubMed 13.Vaxman I, Bernstine H, Kleinstern G, et al. FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma. Hematol Oncol. 2019;37(2):168-175.Google ScholarCrossrefSearch ADS PubMed 14.Voltin CA, Goergen H, Baues C, et al. Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Ann Oncol. 2018;29(9):1926-1931.Google ScholarCrossrefSearch ADS PubMed 15.Weiler-Sagie M, Kagna O, Dann EJ, Ben-Barak A, Israel O. Characterizing bone marrow involvement in Hodgkin’s lymphoma by FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2014;41(6):1133-1140.Google ScholarCrossrefSearch ADS PubMed 16.Adams HJA, Kwee TC, de Keizer B, Fijnheer R, de Klerk JMH, Nievelstein RAJ. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2014;41(3):565-574.Google ScholarCrossrefSearch ADS PubMed 17.Hong J, Lee Y, Park Y, et al. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol. 2012;91(5):687-695.Google ScholarCrossrefSearch ADS PubMed 18.Kaddu-Mulindwa D, Altmann B, Held G, et al. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. Eur J Nucl Med Mol Imaging. 2021;48(11):3550-3559.Google ScholarCrossrefSearch ADS PubMed 19.Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122(1):61-67.Google ScholarCrossrefSearch ADS PubMed 20.National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Hodgkin lymphoma, Version 1.2023. Accessed 1 October 2022. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.21.Nakajima R, Moskowitz AJ, Michaud L, et al. Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. Blood Adv. 2020;4(8):1812-1823.Google ScholarCrossrefSearch ADS PubMed 22.Rutherford SC, Yin J, Pederson L, et al. Relevance of bone marrow biopsies for response assessment in US National Cancer Institute National Clinical Trials Network follicular lymphoma clinical trials. J Clin Oncol. 2023;41(2):336-342.Google ScholarCrossrefSearch ADS 23.Albano D, Giubbini R, Bertagna F. 18F-FDG PET/CT in splenic marginal zone lymphoma. Abdom Radiol (NY). 2018;43(10):2721-2727.Google ScholarCrossrefSearch ADS PubMed 24.Albano D, Durmo R, Treglia G, Giubbini R, Bertagna F. (18)F-FDG PET/CT or PET role in MALT lymphoma: an open issue not yet solved-a critical review. Clin Lymphoma Myeloma Leuk. 2020;20(3):137-146.Google ScholarCrossrefSearch ADS PubMed 25.Park SH, Lee JJ, Kim HO, et al. 18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in 18F-FDG avidity according to site involvement. Leuk Lymphoma. 2015;56(12):3288-3294.Google ScholarCrossrefSearch ADS PubMed 26.Alderuccio JP, Zhao W, Desai A, et al. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. Am J Hematol. 2019;94(5):585-596.Google ScholarCrossrefSearch ADS PubMed 27.Luminari S, Merli M, Rattotti S, et al. Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. Blood. 2019;134(10):798-801.Google ScholarCrossrefSearch ADS PubMed © 2023 by The American Society of Hematology2023 © 2023 by The American Society of Hematology2023 You do not currently have access to this content. Sign in via your Institution

Topics & Concepts